Onsdag 18 November | 10:32:57 Europe / Stockholm
Est. tid*
2026-11-13 - Kvartalsrapport 2026-Q3
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-21 - Kvartalsrapport 2026-Q1
2026-04-15 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2026-04-14 - Årsstämma
2026-02-12 - Bokslutskommuniké 2025
2026-01-26 - Extra Bolagsstämma 2026
2025-11-18 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-30 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2024
2024-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Lytix Biopharma ASA: Key information relating to the subsequent offering

2026-11-18 02:02:09

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND DOES NOT CONSTITUTE A PUBLIC OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 18 November 2026: Reference is made to the stock exchange announcement published by Lytix Biopharma ASA ("Lytix Biopharma" or the "Company") earlier today regarding the successful completion of a private placement (the "Private Placement") and a retail offering (the "Retail Offering") of new shares (the "Offer Shares") raising NOK 80 million in gross proceeds, and a subsequent offering of new shares, at NOK 8.00 per share (the "Subsequent Offering").

The Subsequent Offering will, subject to applicable securities laws, be directed towards existing shareholders in the Company as of 17 November 2026 (as registered in the VPS two trading days thereafter) who (i) were not included in the pre-sounding phase of the Private Placement, (ii) were not allocated Offer Shares in the Private Placement or the Retail Offering, and (iii) are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action (jointly, the "Eligible Shareholders").

The following key information is provided with respect to the Subsequent Offering:

Date for announcement of terms: 18 November 2026

Last day including right: 17 November 2026

First day excluding right: 18 November 2026

Record date: 19 November 2026

Date of approval: The new shares in the Subsequent Offering will be issued pursuant to a board authorisation granted by the Company's extraordinary general meeting on 26 January 2026 (the "Board Authorisation").

Subscription price: NOK 8.00

Other information: The Subsequent Offering, if carried out, will be made at the same price as in the Private Placement and the Retail Offering, NOK 8.00 per share, to raise gross proceeds of up to NOK 15 million. Further details on the Subsequent Offering will be announced separately. Whether the Subsequent Offering is carried out is subject to (i) completion of the Private Placement and the Retail Offering, (ii) the board of directors resolving to issue the new shares under the Board Authorisation, (iii) publication of a national prospectus pertaining to the Subsequent Offering, and (iv) the prevailing market price of the Company's shares together with the corresponding trading volume following the Private Placement. The Company may, in consultation with the Manager (as defined below), decide not to carry out the Subsequent Offering if the Company's shares trade at or below the subscription price in the Subsequent Offering at sufficient volumes.

Advisors:

DNB Carnegie, a part of DNB Bank ASA, is acting as sole bookrunner (the "Manager").

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.

Disclosure regulation:

This information is subject to a duty of disclosure pursuant to the Company's continuing obligations as a company listed on Euronext Growth.

For further information, please contact:

Gjest Breistein, CFO

gjest.breistein@lytixbiopharma.com

+47 952 60 512

About Lytix Biopharma

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to effectively prime durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker LYTIX.

Important information:

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation or other investors who can receive the offer in reliance on an applicable exemption from the obligation to publish a prospectus, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The "Prospectus Regulation" means Regulation (EU) 2017/1129, as amended (together with any applicable implementing measures) in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"), and in each case only in circumstances falling within Part 1 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024 (the "POATRs"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

The issue, subscription or purchase of shares or other financial instruments in the Company is subject to specific legal or regulatory restrictions in certain jurisdictions. Neither the Company nor the Manager assumes any responsibility in the event there is a violation by any person of such restrictions. The distribution of this release may in certain jurisdictions be restricted by law. Persons into whose possession this release comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. Any forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Such assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not make any guarantee that the assumptions underlying any forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on any forward-looking statements in this announcement. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

This announcement is made by, and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Manager nor any of its affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. This announcement is an advertisement and is not a prospectus for the purposes of the Prospectus Regulation as implemented in any Member State.